ReviewCancer cell international2026
The oral microbiota in oral squamous cell carcinoma: unravelling mechanisms and clinical potential.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Originating in the mucosal lining of the mouth, oral squamous cell carcinoma is the most common malignancy of the head and neck regions. Its pathogenesis is multifactorial, involving environmental exposures, genetic susceptibility, and lifestyle-related risk factors. Increasing evidence indicates that oral microbial dysbiosis contributes to the initiation and progression of OSCC. Under healthy conditions, the oral cavity harbors a diverse and functionally balanced microbial ecosystem that maintains mucosal integrity, supports immune homeostasis, and prevents colonization by pathogenic species. Disruption of this equilibrium, known as oral dysbiosis, is increasingly recognized as a key event in oral carcinogenesis. In OSCC, a shift toward pathogenic and pro-inflammatory microbial communities has been consistently observed, particularly involving periodontal bacteria such as Porphyromonas gingivalis, Treponema denticola, and Fusobacterium nucleatum. These organisms contribute to tumor progression by activating inflammatory and oncogenic signaling pathways, including NF-κB, STAT3, and PI3K/Akt; suppressing apoptosis; inducing epithelial-mesenchymal transition; and immune evasion, thereby creating a tumor-promoting microenvironment. In addition to bacterial dysbiosis, viral and fungal components of the oral microbiome may act as important cofactors in OSCC. High-risk Epstein-Barr virus (EBV) and human papillomavirus (HPV) have been implicated in disrupting tumor suppressor pathways, causing genomic instability, and modulating the immune response. Fungal species, particularly Candida albicans, may further contribute by producing carcinogenic metabolites and inducing chronic inflammation. This review provides an integrated overview of the oral microbiome in OSCC, focusing on the composition and protective roles of the core microbiota, factors influencing microbial stability, and mechanisms by which dysbiosis contributes to carcinogenesis. It also highlights the oral microbiome as a potential source of non-invasive biomarkers and discusses microbiome-targeted strategies, including prebiotics, probiotics, and postbiotics, as promising adjunctive approaches to restore microbial balance and reduce tumor-promoting inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.